These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15140235)

  • 1. Reduced expression of insulin-like growth factor-binding protein-3 (IGFBP-3) in Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa.
    Mallipeddi R; Wessagowit V; South AP; Robson AM; Orchard GE; Eady RA; McGrath JA
    J Invest Dermatol; 2004 May; 122(5):1302-9. PubMed ID: 15140235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
    Arnold AW; Bruckner-Tuderman L; Zuger C; Itin PH
    Dermatology; 2009; 219(1):80-3. PubMed ID: 19439919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa-Hallopeau-Siemens: a report of four cases.
    Dammak A; Zribi J; Boudaya S; Mseddi M; Meziou TJ; Masmoudi A; Ellouze Z; Keskes H; Turki H
    Int J Dermatol; 2009 Jun; 48(6):588-91. PubMed ID: 19538366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl.
    Shivaswamy KN; Sumathy TK; Shyamprasad AL; Ranganathan C
    Int J Dermatol; 2009 Jul; 48(7):731-3. PubMed ID: 19570079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression.
    Pourreyron C; Cox G; Mao X; Volz A; Baksh N; Wong T; Fassihi H; Arita K; O'Toole EA; Ocampo-Candiani J; Chen M; Hart IR; Bruckner-Tuderman L; Salas-Alanis JC; McGrath JA; Leigh IM; South AP
    J Invest Dermatol; 2007 Oct; 127(10):2438-44. PubMed ID: 17495952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.
    Arbiser JL; Fan CY; Su X; Van Emburgh BO; Cerimele F; Miller MS; Harvell J; Marinkovich MP
    J Invest Dermatol; 2004 Oct; 123(4):788-90. PubMed ID: 15373786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
    Kim M; Murrell DF
    Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
    Cho RJ; Alexandrov LB; den Breems NY; Atanasova VS; Farshchian M; Purdom E; Nguyen TN; Coarfa C; Rajapakshe K; Prisco M; Sahu J; Tassone P; Greenawalt EJ; Collisson EA; Wu W; Yao H; Su X; Guttmann-Gruber C; Hofbauer JP; Hashmi R; Fuentes I; Benz SC; Golovato J; Ehli EA; Davis CM; Davies GE; Covington KR; Murrell DF; Salas-Alanis JC; Palisson F; Bruckner AL; Robinson W; Has C; Bruckner-Tuderman L; Titeux M; Jonkman MF; Rashidghamat E; Lwin SM; Mellerio JE; McGrath JA; Bauer JW; Hovnanian A; Tsai KY; South AP
    Sci Transl Med; 2018 Aug; 10(455):. PubMed ID: 30135250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
    Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
    Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.
    Kivisaari AK; Kallajoki M; Mirtti T; McGrath JA; Bauer JW; Weber F; Königová R; Sawamura D; Sato-Matsumura KC; Shimizu H; Csikós M; Sinemus K; Beckert W; Kähäri VM
    Br J Dermatol; 2008 Apr; 158(4):778-85. PubMed ID: 18284387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa.
    Knaup J; Gruber C; Krammer B; Ziegler V; Bauer J; Verwanger T
    Anal Cell Pathol (Amst); 2011; 34(6):339-53. PubMed ID: 22002724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC.
    Martins VL; Caley MP; Moore K; Szentpetery Z; Marsh ST; Murrell DF; Kim MH; Avari M; McGrath JA; Cerio R; Kivisaari A; Kähäri VM; Hodivala-Dilke K; Brennan CH; Chen M; Marshall JF; O'Toole EA
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa.
    Rokunohe A; Nakano H; Aizu T; Kaneko T; Nakajima K; Ikenaga S; Matsuzaki Y; Murai T; Tamai K; Sawamura D
    J Dermatol; 2008 Jun; 35(6):336-40. PubMed ID: 18578710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 13-year-old girl with recessive dystrophic epidermolysis bullosa presenting with squamous cell carcinoma.
    Ayman T; Yerebakan O; Ciftçioglu MA; Alpsoy E
    Pediatr Dermatol; 2002; 19(5):436-8. PubMed ID: 12383103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.
    Tartaglia G; Cao Q; Padron ZM; South AP
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recessive dystrophic epidermolysis bullosa-associated squamous-cell carcinoma: an enigmatic entity with complex pathogenesis.
    Rodeck U; Uitto J
    J Invest Dermatol; 2007 Oct; 127(10):2295-6. PubMed ID: 17853916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas.
    Illmer J; Zauner R; Piñón Hofbauer J; Wimmer M; Gruner S; Ablinger M; Bischof J; Dorfer S; Hainzl S; Tober V; Bergson S; Sarig O; Samuelov L; Guttmann-Gruber C; Shalom-Feuerstein R; Sprecher E; Koller U; Laimer M; Bauer JW; Wally V
    Br J Dermatol; 2023 Dec; 190(1):80-93. PubMed ID: 37681509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa.
    Hata H; Abe R; Suto A; Homma E; Fujita Y; Aoyagi S; Shimizu H
    Br J Dermatol; 2015 Mar; 172(3):769-73. PubMed ID: 25066310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and Outcome of Squamous Cell Carcinoma in Epidermolysis Bullosa in Australia and New Zealand.
    Kim M; Li M; Intong-Wheeler LRA; Tran K; Marucci D; Murrell DF
    Acta Derm Venereol; 2018 Jan; 98(1):70-76. PubMed ID: 28853495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of transforming growth factor-β1 in recessive dystrophic epidermolysis bullosa squamous cell carcinoma.
    Twaroski K; Chen W; Pickett-Leonard M; Tolar J
    Exp Dermatol; 2021 May; 30(5):664-675. PubMed ID: 33595864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.